Early clinical research
ARMADA — armored CAR-T (DLL3+ cancers, phase I)
A Phase I Trial for R/R MetAstatic DLL3+ Cancers Utilizing Armored CAR T Cells (ARMADA)
- Phase
- Phase I
- Recruitment
- Recruiting
- Results maturity
- No results
- Publication
- No publication
- Regulatory approval
- No regulatory approval
- NCT
- NCT07783477
- Registry checked
- 2026-10-29
- Editorial update
- 2026-10-29
Not a treatment recommendation. Experimental or ongoing research does not by itself replace standard care.
For patients
What is being studied? Immune cells engineered to recognize cancer are being tested in an early safety study.
Why promising? Early clinical test of armored CAR-T safety in solid-tumor settings.
What is not proven? Efficacy; generalization to GI adenocarcinoma; approval.
Is this standard care today? This listing alone does not replace standard care; approval and guideline context require clinician judgment.
For clinicians
Phase I; recruiting. No results yet.
Cancer / population: Multiple / solid tumors — Relaps/refrakter metastatik DLL3+ kanserler (protokol; örn. nöroendokrin / SCLC bağlamı)
Intervention: Zırhlandırılmış CAR-T hücreleri
Primary endpoint: Güvenlik / DLTs
Limitations: DLL3+ seçimi; hematolojik CAR-T sonuçlarıyla karıştırılmamalı.